Quick Answer
AEON Biopharma, Inc. reported Cash And Cash Equivalents At Carrying Value of $3.01 million for the year ending 2025.
- AEON Biopharma, Inc. showed an increase of +23,023.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from AEON Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2021 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $1.44 million | Q2 2021: $988.9 thousand | Q3 2021: $663.5 thousand | Q4 2021: $497.4 thousand | Q1 2022: $166.2 thousand | Q2 2022: $7.8 thousand | Q3 2022: $27.8 thousand | Q3 2023: $16.18 million | Q1 2024: $1.56 million | Q2 2024: $3.44 million | Q3 2024: $537.0 thousand | Q1 2025: $10.45 million | Q2 2025: $8.44 million | Q3 2025: $5.93 million.
- Over the full 6 years of available data (2021 to 2025), AEON Biopharma, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 504.3%.
- Historical annual values: Fiscal year 2025: $3.01 million | Fiscal year 2024: $13.0 thousand | Fiscal year 2023: $5.16 million | Fiscal year 2023: $31.20 million | Fiscal year 2022: $9.75 million | Fiscal year 2021: $497.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: